Investor Relations

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company is focused on developing and commercializing its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for Renal Cell Carcinoma and other cancers. AVEO is leveraging multiple partnerships to develop and commercialize tivozanib in non-oncologic indications worldwide and oncology indications outside of North America, as well as to progress its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome).

NASDAQ | AVEO (Common Stock)
$0.97 - 0.02
Stock chart for: AVEO.O.  Currently trading at $0.97 with a 52 week high of $1.57 and a 52 week low of $0.82.
08/25/16 4:00 p.m. ET
Data Provided by Thomson Reuters

Press Releases

AVEO Initiates the Evaluation of Tivozanib in Combination with Bristol-Myers Squibb’s Opdivo® (nivolumab) in Advanced Renal Cell CarcinomaRead More
AVEO Oncology Reports Second Quarter 2016 Financial Results and Provides Business UpdateRead More
AVEO to Present at the 2016 JMP Securities Life Science ConferenceRead More